Literature DB >> 6627244

The oxazaphosphorines.

N Brock.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6627244     DOI: 10.1016/s0305-7372(83)80002-4

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


× No keyword cloud information.
  14 in total

1.  The effect of age on the pharmacokinetics of ifosfamide.

Authors:  M J Lind; J M Margison; T Cerny; N Thatcher; P M Wilkinson
Journal:  Br J Clin Pharmacol       Date:  1990-07       Impact factor: 4.335

2.  Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution.

Authors:  M J Lind; J M Margison; T Cerny; N Thatcher; P M Wilkinson
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 3.  Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.

Authors:  T Kerbusch; J de Kraker; H J Keizer; J W van Putten; H J Groen; R L Jansen; J H Schellens; J H Beijnen
Journal:  Clin Pharmacokinet       Date:  2001-01       Impact factor: 6.447

4.  Alkylating activity in serum, urine, and CSF following high-dose ifosfamide in children.

Authors:  J Ninane; R Baurain; J de Kraker; A Ferster; A Trouet; G Cornu
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

5.  A phase II study of ifosfamide in children with recurrent solid tumours.

Authors:  C R Pinkerton; H Rogers; C James; A Bowman; P R Barbor; O B Eden; J Pritchard
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

6.  Continuous 5-day infusion of ifosfamide with mesna in inoperable pancreatic cancer patients: a phase II study.

Authors:  T Cerny; G Martinelli; A Goldhirsch; F Terrier; R Joss; M F Fey; K W Brunner; A Küpfer
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

Review 7.  Comparative activity of ifosfamide and cyclophosphamide.

Authors:  W Brade; S Seeber; K Herdrich
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

8.  VP 16 plus ifosfamide plus cisplatin as salvage therapy in refractory testicular cancer.

Authors:  L H Einhorn
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

9.  A phase II study of ifosfamide in paediatric solid tumours.

Authors:  C R Pinkerton; J Pritchard
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

10.  Differential effects of ifosfamide on dendritic cell-mediated stimulation of T cell interleukin-2 production, natural killer cell cytotoxicity and interferon-gamma production.

Authors:  M C Kuppner; E Bleifuss; E Noessner; R Mocikat; C von Hesler; C Mayerhofer; R D Issels
Journal:  Clin Exp Immunol       Date:  2008-07-18       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.